Print Page  |  Close Window

Investor Overview

We are a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of patients' lives.

Using our proprietary sublingual spray technology and our capability to develop pharmaceutical cannabinoids, Insys addresses the clinical shortcomings of existing commercial products. Insys currently markets two products, Subsys®, which is sublingual Fentanyl spray for breakthrough cancer pain, and a generic version of Dronabinol (THC) capsules.

In March 2012, we launched Subsys® , our proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in adult opioid-tolerant patients, through our cost-efficient commercial organization of approximately 250 sales professionals.

Since late 2014, Subsys® has been the most prescribed transmucosal immediate-release fentanyl, or TIRF, product with 48% market share on a prescription basis, according to IMS.

In December 2011, we launched Dronabinol SG Capsule, a generic equivalent to Marinol (dronabinol), an approved second-line treatment for chemotherapy-induced nausea and vomiting, or CINV, and anorexia associated with weight loss in patients with AIDS, through our exclusive distributor, a leading generic pharmaceutical company.

Our lead product candidate is Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol, which would be our second branded supportive care product, if approved. We intend to market Dronabinol Oral Solution and any other future supportive care products, if approved, through our commercial organization.

Please see full prescribing information for Subsys® including the boxed warning.

Recent News

Feb 15 2017
Insys Therapeutics Announces Use of Cannabidiol Oral Solution for Compassionate Use Studies in Patients Completing Long-Term Safety Study
CHANDLER, Ariz., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") today announced that the Company is providing for the use of Cannabidiol Oral Solution at doses up to 40 mg/kg/day in compassionate use studies... 
Feb 14 2017
Insys Therapeutics, Inc. to Present at 2017 RBC Capital Markets Global Healthcare Conference
PHOENIX, Feb. 14, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (“Insys” or “the Company”) (NASDAQ:INSY) today announced that Santosh Vetticaden, MD, PhD, Interim Chief Executive Officer, and Chief Medical Officer, and Darryl Baker, Chief Financial Officer... 
Jan 09 2017
Insys Therapeutics Announces Retirement of Dr. John N. Kapoor as CEO and Chairman; Appoints Dr. Santosh Vetticaden as Interim CEO and Steven Meyer as Chairman of the Board
PHOENIX, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") today announced that Dr. John N. Kapoor, its Founder, President and Chief Executive Officer (“CEO”) and Chairman of the Company’s Board of Directors (“... 
see all news